BRAF is a cytoplasmic protein kinase, which activates the MEK-ERK signalling pathway. Deregulation of the pathway is associated with the presence of BRAF mutations in human cancer, the most common being V600E BRAF, although structural rearrangements, which remove N-terminal regulatory sequences, have also been reported. RAF-MEK-ERK signalling is normally thought to occur in the cytoplasm of the cell. However, in an investigation of BRAF localisation 
Introduction
There are three members of the mammalian RAF protein kinase family: ARAF, BRAF and CRAF. Oncogenic forms of the RAFs, encoding only their C-terminal kinase domains, were originally identified as transforming genes in oncogenic retroviruses of mice and chickens [1] . RAF proteins share three conserved regions (CR) 1e3, with CR3 encoding the kinase domains in the C-termini. This region is the most homologous amongst the three RAFs, showing >75% identity [2] , and its activity is suppressed by the N-terminus [3] .
RAF protein kinases play a key role in intracellular signalling by linking RAS activity with the Mitogen-activated protein kinase kinase (MEK)-Extracellular signalRegulated Kinase (ERK) signalling pathway. Deregulation of the pathway is associated with numerous pathologies [4] , most notably cancer, and RAF mutations are frequently found in cancer samples. In mice and chickens, as mentioned, this is evident in the form of N-terminal truncations, which generate oncoproteins with transforming activity. In human cancers, mutations in BRAF are more frequent than mutations in either ARAF or CRAF [5] , most commonly through the acquisition of nucleotide substitutions such as that encoding the V600E BRAF mutant [6] .
Although N-terminal truncations of RAF are rare in human cancers, chromosomal translocations that delete the N-terminal regulatory domain of BRAF have been reported in multiple cancer types [7, 8] as well as aberrant spliced BRAF variants that delete the RAS binding domain in cells resistant to the BRAF inhibitor vemurafenib [9] . In the vast majority of cases, BRAF mutations are gain-of-function that mediate oncogenic effects through elevated BRAF kinase activity [8, 10, 11] .
In a well-accepted model of RAF-MEK-ERK signalling [12] , RAF is held in the cytoplasm in an inactive conformation bound to 14-3-3 through phosphorylated serine residues at S729 and S365. Following stimulation of cell surface receptors and the subsequent conversion of RAS to its GTP-bound active form, 14-3-3 binding to RAF is disrupted, RAS binds to the N-terminal domain of RAF, RAF dimerises and is translocated to the plasma membrane where it becomes active. RAF can then phosphorylate MEK1/2 at two serine residues in their activation loop and this active MEK phosphorylates threonine and tyrosine residues in the TEY motif of ERK1/2 to activate it. ERK is a pleiotropic kinase and can phosphorylate many substrates in nearly all cell compartments to elicit different biological effects [13, 14] . There is considerable evidence to show that cell cycle entry is dependent on the nuclear accumulation of active ERK, leading to phosphorylation of transcription factors and propagation of immediate early gene and protein expression [13, 15, 16] .
The mechanism of ERK transport across the nuclear pore is complex, with evidence
showing it occurs by energy-dependent and eindependent mechanisms [17] . ERK lacks a canonical Nuclear Localisation Signal (NLS) and does not interact with importinab but relies on interaction with a range of proteins for appropriate localisation within the cell [18, 19, 20] . Energy-independent nuclear import of ERK is facilitated by interaction with nuclear pore proteins. Stimulus-dependent ERK nuclear import involves phosphorylation of ERK by MEK and disruption of the MEK-ERK association in the cytoplasm [21, 22] as well as abrogation of the interaction between ERK and other cytoplasmic anchors through ERK's D-domain [23] . A possible mechanism for ERK nuclear import may be through a Nuclear Translocation Signal (NTS) within an SPS motif in the ERK kinase insertion domain [24] . Phosphorylation of two serine residues in this motif has been suggested to allow interaction with importin7, release from interaction with nuclear pore proteins and subsequent nuclear entry [24] . MEK functions as a cytoplasmic anchor for ERK although it is also capable of entering the nucleus upon cellular stimulation and detachment from ERK [21, 24, 25] . However, MEK is exported from the nucleus much faster than ERK due to a nuclear export signal (NES), a leucine-rich sequence in its N-terminus [24, 25] , that allows its rapid Crm1-dependent nuclear export.
Despite the overwhelming evidence supporting a cytoplasmic location of RAF proteins and their translocation to the plasma membrane upon activation [16, 26] , there are reports of alternative locations within the cell. BRAF in particular has been detected in mitochondria [27] , Golgi [28, 29] , the mitotic spindle [30] and the nucleus [31, 32] , and this compartmentalisation is associated with distinct biological outcomes in some circumstances [27, 30, 32] . For example, a portion of BRAF has been detected at spindle poles and kinetochores in mitotic HeLa cells and knockdown of BRAF using siRNA resulted in early exit of cells from mitosis, perturbation of Mps1 localisation and the formation of pleiotropic spindle abnormalities and misaligned chromosomes [30] . BRAF isoforms have also been detected in nuclear fractions of the rat forebrain and cerebellum [31] with a recent investigation identifying BRAF in the nucleus of skeletal muscle cells after activation, where it was found to interact with and phosphorylate PAX3 leading to enhancement of MET activity, a requirement for limb muscle precursor cell migration [32] . However, the relevance of these alternative locations for BRAF and their role in downstream MEK/ERK signaling and BRAF-driven oncogenesis has not been fully explored as yet.
In this study, we have used tagged, exogenously expressed RAF proteins in NIH3T3 cells combined with fluorescence microscopy and fractionation methods to evaluate BRAF compartmentalisation in more detail. Surprisingly, we detect the accumulation of N-terminally truncated forms of BRAF in the nucleus whereas full length, wild-type BRAF and V600E BRAF are detected in the nucleus to a lower extent.
Here, we correlate the compartmentalisation of these GFP-tagged forms of BRAF with the localisation of MEK and ERK in NIH3T3 cells.
Materials and methods

Vectors
To generate GFP-RAF expression vectors, cDNAs expressing wild-type or mutant versions of BRAF or CRAF were cloned into pEGFP-C1 vector (Clontech). GFP-DBRAF contains residues 449-804 of mouse BRAF, GFP-DCRAF contains residues 306-648 of human CRAF, GFP-FL-WT BRAF contains residues 1-766 of human BRAF and GFP-FL-V600E BRAF contains residues 1-766 of human BRAF with the V600E mutation. The human KIAA1549:BRAF and human WT BRAF cDNAs cloned within the pcDNA3.1 expression vector have been reported previously [33] . Mutations within GFP-DBRAF or GFP-FL-WT BRAF were generated by performing site-directed mutagenesis using the GeneTailor TM system (Thermo Fisher, 12397). Adenoviruses expressing human GFP-FL-WT BRAF or human GFP-DBRAF were generated by using the methods previously described [34] . Craf or wild-type controls were derived and cultured as reported previously [35] . MEFs expressing endogenous oncogenic G12D KRAS or wild-type controls were derived and cultured as reported previously [36] . Cells were transfected using a Nucleofector under conditions recommended by the manufacturer (Amaxa Biosystems) as previously described [37] . NIH3T3 cells stably expressing DBRAF:ER or DCRAF:ER have been previously reported [38] . These cells were cultured as for NIH3T3 cells and were treated with 1 mM 4-hydroxytamoxifen (4-HT; Sigma, T-176) or 100% ethanol as carrier control for 24 or 48 hours before analysis. Cells were treated with 20 nM Leptomycin B (LMB; Cell Signaling, 9676) or carrier control (100% ethanol) for 3 hours before analysis in some experiments.
Cell culture
Fluorescence microscopy
Forty-eight hours after transfection with GFP vectors, cells were counterstained with 1 mg/ml 4 0 ,6-diamidino-2-phenylindole (DAPI), processed and GFP/DAPI fluorescence was visualized by fluorescence microscopy as previously described [39] . For immunofluorescence of RAF:ER fusion proteins, cells were processed as previously described [40] and immunostained by indirect immunofluorescence with a rabbit polyclonal anti-ERa antibody (Santa Cruz SC-543) as the primary antibody and an AlexaFluorÒ 568-conjugated anti-rabbit IgG Fab as the secondary antibody before counterstaining with DAPI. The staining pattern in each cell was classified by user analysis into one of three categories: a) nuclear less than cytoplasmic (N < C), b) equally distributed (N¼C), c) nuclear greater than cytoplasmic (N > C).
Epifluorescence images were taken on an inverted Nikon TE300 microscope with
Hamamatsu ORCA-ER digital camera and X-cite 120 fluorescence illumination system controlled by Improvision's Openlab software.
Protein analysis
For fractionation, cytoplasmic and nuclear fractions were prepared by using the NE-PER TM kit (Thermo Fisher, 78833) following the manufacturer's instructions.
Whole cell Triton X-100 soluble lysates were prepared as described [41] . For western blot analysis, the following antibodies were used: GFP (Abcam, ab6556), a- 
Statistical analysis
Comparison between two groups was performed by the unpaired t test with Welch's correction using Prism software version 7. The data are presented as the mean value and the error bars indicate AESD or AESEM (as indicated). Significance is indicated as *** for p < 0.001, ** for p < 0.01, * for p < 0.05 and not significant (NS) for p values > 0.05. For HCM, correlation coefficients were determined and compared using R package cocor (cran.r-project.org/web/packages/cocor/index.html).
Results
Localisation of GFP-tagged RAF fusion proteins
To further understand the role of BRAF within the cell, we investigated its subcellular localisation. In initial experiments, immunofluorescence was performed using a well-utilised BRAF antibody that has previously been shown to detect BRAF protein species by Western blot analysis of wild-type MEFs that disappear in Braf À/À MEFs [44] . Despite this apparent specificity, a weak immunofluorescence signal was detected in Braf À/À cells with the same antibody, whereas no signal was seen with the secondary antibody alone (Fig. S1 ). These results show that immunofluorescence staining for BRAF is unreliable. We therefore resorted to using fluorescence microscopy of GFP-tagged, exogenously expressed proteins combined with subcellular fractionation.
cDNAs encoding either full-length BRAF (FL-WT BRAF) or the kinase domain of BRAF (DBRAF) were fused in-frame to a cDNA expressing GFP, generating N-terminal GFP tagged fusion cDNAs (Fig. 1A) . The constructs were expressed in NIH3T3 cells and the staining patterns were evaluated. GFP-FL-WT BRAF showed mostly cytoplasmic staining but, unexpectedly, GFP-DBRAF demonstrated heterogeneous staining with evidence of both cytoplasmic and nuclear expression (Fig. 1A) . A similar analysis with a fusion construct expressing GFP-DCRAF showed mostly cytoplasmic staining while a vector expressing the GFP tag alone showed mostly nuclear staining (Fig. 1A ).
The staining pattern in each cell was classified into one of three categories: nuclear less than cytoplasmic (N < C), equally distributed (N¼C) or nuclear greater than cytoplasmic (N > C) (Fig. 1B) . Staining was quantified for each construct. For show nuclear enrichment with LMB. This suggests a dynamic movement of the fusion proteins between the nucleus and cytoplasm (Fig. 1B) , but not for monomeric GFP. GFP-DBRAF staining in the nucleus was shown to be real and intense by performing a Z series through a nuclear-stained cell using confocal microscopy imaging
To confirm the microscopy data, subcellular fractionation was performed. As with the fluorescence microscopy, monomeric GFP and GFP-DBRAF were robustly detected in cytoplasmic and nuclear fractions in NIH3T3 cells, whereas both GFP-FL-WT BRAF (Fig. 1C ) and GFP-DCRAF (Fig. 1D ) were detected at lower levels in this fraction. Consistent with the data for GFP-FL-WT BRAF, endogenous BRAF was also predominantly cytoplasmic although low levels of slower migrating isoforms were detected in the nucleus (Fig. 1E ).
To gain a handle on the proportion of GFP-DBRAF in the nucleus, we assumed 100% nuclear localization for N > C cells, 100% cytoplasmic staining for N < C cells and 50:50 nuclear/cytoplasmic staining for N¼C cells. Using these values, for GFP-DBRAF, w39% locates to the nucleus and this increases to w52% in the presence of LMB. For both GFP-FL-WT BRAF and GFP-DCRAF, w8% is located in the nucleus and this rises to w25% in the presence of LMB. Monomeric GFP showed w80% nuclear compartmentalisation. Determination of the Nuclear:Cytoplasmic (N:C) proportion by quantitation of western blots showed a broadly similar trend with mean values of 44% for GFP-DBRAF, 20% for GFP-FL-WT BRAF and 14% for GFP-DCRAF (Fig. 1F) , although monomeric GFP showed less nuclear compartmentalisation by this method with a mean value of 44%. Quantitation of western blots, also generated a mean value of 18% for compartmentalisation of endogenous BRAF in the nucleus of NIH3T3 cells (Fig. 1F ).
GFP fusion is used extensively as a method to study protein compartmentalisation and subcellular localisation. The main problem for nuclear localisation studies with GFP is that GFP translocates to the nucleus on its own by diffusion through the nuclear pore and, indeed, we detected the accumulation of monomeric GFP in the nucleus (Fig. 1A , B, C, F) consistent with previous observations [45] . Despite this, the fact that GFP-DBRAF and GFP-DCRAF both contain GFP and are of a similar size but have different distributions between the nucleus and cytoplasm is supportive of the RAF components being the major determinant of their compartmentalisation.
Localisation of hbER fusion proteins
To further rule out a role of the GFP tag, we assessed a different tag by using DBRA-F:ER and DCRAF:ER, which represent fusions of the BRAF and CRAF kinase domains with the hormone binding domain of the oestrogen receptor (hbER) [38] ( Fig. 2A) . hbER-fusion proteins have been used extensively to investigate the downstream biological functions of a range of signaling proteins including MYC [46] , ABL [47] , and RAF [38, 48, 49] . Although the intact oestrogen receptor has the ability to localise to the nucleus, this function has been attributed to a Nuclear Localisation Signal (NLS) within the DNA binding domain and not the hormone binding domain [37, 50] . Control of chimeric hbER-fusion proteins is conferred by hormone-induced displacement of HSP90 binding leading to fusion protein stabilisation [51] .
We used immunofluorescence with an ER antibody to determine the subcellular localisation of DBRAF:ER and DCRAF:ER stably expressed in NIH3T3 cells [38] before and after treatment with the anti-oestrogen 4-hydroxytamoxifen (4-HT). In the absence of 4-HT, there was weak staining reflecting the low levels of expression of the fusion proteins ( Fig. 2A) . In the presence of 4-HT, higher levels of stabilised proteins were observed with DCRAF:ER showing mostly cytoplasmic distribution and DBRAF:ER showing nuclear and cytoplasmic localisation ( Fig. 2A) . To obtain quantitative data, the staining pattern of each cell was categorised as above for Fig. 1B . We found a significant difference in the compartmentalisation of DBRA-F:ER compared to DCRAF:ER following 4-HT treatment (Fig. 2B) , with DBRA-F:ER having significantly more N > C cells (w38% compared to 0%) and N¼C cells (w57% compared to w8%) than DCRAF:ER with N < C cells reducing as a consequence (w5% compared to w92%). Fractionation was also undertaken and confirmed the observation that DBRAF:ER has a greater propensity to accumulate in the nucleus than DCRAF:ER following induction with 4-HT (Fig. 2C) . Quantitation of western blot data showed 32e40% of DBRAF:ER in the nucleus as opposed to 6e10% for DCRAF:ER (Fig. 2D ). These data are consistent with the results obtained for the GFP-tagged, exogenously-expressed proteins (Fig. 1) .
Localisation of BRAF mutants detected in human cancers
We next investigated if the difference in distribution of full length versus N-terminally truncated BRAF also applied to mutant versions of BRAF that are detected in human cancers. A fusion construct was generated in which a cDNA for GFP was fused in-frame to a cDNA encoding human V600E BRAF and this was expressed in NIH3T3 cells (Fig. 3A) . Fluorescence microscopy was performed and the staining patterns quantitated (Fig. 3A) . This showed 0% of cells with N > C staining, w8% with N¼C staining and w92% with N < C staining. This distribution was not affected by LMB (Fig. 3A) . Fractionation confirmed very low levels of GFP-V600E-BRAF nuclear compartmentalisation (Fig. 3B) , which was quantitated at w9%
Although rare, over 50 different translocations involving the BRAF gene have been detected in human cancers, many associated with removal of the BRAF N-terminal regulatory domain and expression of novel fusion proteins with the BRAF C-terminal kinase domain [8] . We analysed the location of one such mutation involving exons 8e16 of the KIAA1549 gene fused to the C-terminal domain (exons 9e18) of BRAF (SK:B) reported in human pilocytic astrocytomas [33] . A vector expressing this fusion protein was transiently transfected into NIH3T3 cells and was found to show a greater level of accumulation in the nucleus than FL-WT BRAF as determined by fractionation and western blot analysis using a C-terminal antibody for BRAF (Fig. 3C) . Indeed, quantitation of western blot data showed w70% of SK:B in the nuclear compartment, suggesting a contribution of the KIAA1549 translocation partner in its nuclear compartmentalisation.
Apart from the nuclear-localising potential of truncated BRAF, the subcellular localisation of each BRAF fusion protein could also be affected by the nature of the fusion partner, as found with SK:B (Fig. 3C ). We performed cellular component ontology analysis of 55 gene partners for BRAF detected in human cancers and found 16 (29%) with the potential to locate to the nuclear compartment (Table S1 ). Thus, unlike V600E BRAF, at least in some circumstances, fusion proteins in which the N-terminus of BRAF is replaced by a novel fusion partner have the potential to locate to the nucleus, whether this be mediated by the BRAF component or the fusion partner. 
Canonical nuclear localisation signals are not present in DBRAF
The fact that LMB enriches DBRAF in the nucleus (Fig. 1B) indicates that the protein can shuttle in and out of this compartment. Unlike MEK and ERK [24] , mammalian DBRAF does not possess a purported NTS with the S/T-P-S/T sequence and, in contrast to MEK, DBRAF also does not possess a Crm1-dependent leucine-rich canonical NES.
To search for a canonical NLS we used the PSORT algorithm (https://psort.hgc.jp), which searches for sequences homologous to the classical NLS of the SV40 large T antigen. This analysis identified a potential bipartite NLS at residues 689-704 of human BRAF that is conserved in several including D. rerio and X. laevis (Fig. 4A) . The contiguous nature of basic amino acids in this sequence is disrupted in CRAF and ARAF as well as in the RAF homologues of C. elegans and D. melanogaster (Fig. 4A) . The 3D structure of the kinase domain shows the putative bipartite NLS of BRAF lies in a loop region, exposed to potential solvent and binding partners (Fig. 4B ).
To examine whether this putative NLS sequence is functional, we created two different types of mutations in mouse GFP-DBRAF: a) K737V and/or R738K mutation in order to create sequences analogous to those in CRAF; b) combined K727A, R728A, K735A, K736A, K737A mutations to disrupt contiguous basic amino acids. None of these mutation strategies altered GFP-DBRAF compartmentalisation as determined by fractionation following expression in NIH3T3 cells (Fig. 4C, D) , suggesting that the mechanisms governing import of DBRAF do not conform to the classical NLS model.
To investigate mobility of DBRAF in real time, FRAP was performed for GFP-DBRAF or monomeric GFP in NIH3T3 cells after photobleaching of the nuclei of GFP-expressing cells. There was rapid, almost complete nuclear recovery of monomeric GFP indicating that GFP moves freely between compartments (Fig. 4E and  Fig. S3 ). This is consistent with the observation that GFP localisation is not sensitive to LMB treatment (Fig. 1B) . GFP-DBRAF showed slower recovery and with a lower mobile fraction (Fig. 4E and Fig. S3 ). These data show that DBRAF-GFP movement to the nucleus was more complex than monomeric GFP and possibly involves the regulation of multiple populations with differing translocation rates.
BRAF nuclear compartmentalisation is suppressed by the CR1 domain
The fact that GFP-DBRAF has the potential to accumulate in the nucleus whereas GFP-FL-WT BRAF does not accumulate to the same extent suggests possible tethering of full length BRAF in the cytoplasm through its N-terminal domain. RAF proteins are known to hetero-dimerise [52] and therefore we tested the roles of CRAF and ARAF in BRAF compartmentalisation. There was no difference in the (Fig. 5A ) while, in Araf knockout MEFs, there was a small but significant decrease in nuclear compartmentalisation of both fusion proteins (Fig. 5B) . However, overall, these data identify no role for heterodimerisation in the tethering of the full-length protein in the cytoplasm.
We also examined a role of RAS by expressing GFP-FL-WT BRAF and GFP-DBRAF in MEFs expressing oncogenic G12D KRAS and found that there was no significant difference in compartmentalisation compared to wild-type MEFs (Fig. 5C ).
Consistently, there was no significant difference in the compartmentalisation of GFP-FL-R188L BRAF, which bears a mutation preventing RAS binding as assessed by both fluorescence microscopy ( Fig. 5D ) and fractionation (Fig. 5E ). Creation of mutations in the 14-3-3 binding residue at S729A in GFP-FL-BRAF showed a small but significant increase in nuclear compartmentalisation as assessed by fluorescence microscopy ( Fig. 5D ) but this was not validated by fractionation (Fig. 5E ).
There was also no significant difference with respect to mutation of the S365 14-3-3 binding site (Fig. 5D , E).
It should be noted that, throughout our experiments, we observed some variability in the level of nuclear/cytoplasmic compartmentalisation of both GFP-FL-WT BRAF and GFP-DBRAF in NIH3T3 cells (Fig. 1B) compared to the wild-type MEFs used in Fig. 5 . We compared the pattern of staining more directly but found there was no significant difference between the cell types except for slightly increased nuclear staining of GFP-DBRAF in Araf WT cells compared to NIH3T3 cells (Fig. S4) .
The reason for this is not clear but may be reflective of the cellular origin of these different fibroblastic cell lines.
To investigate the role of the N-terminus in tethering full-length BRAF in the cytoplasm, we created serial truncations of human full-length WT BRAF (Fig. 6A ) and found that increasing the size of the deletion from the N-terminus (w110 KDa to w65 KDa including GFP) progressively increased BRAF nuclear accumulation with both the CR1 domain and BRAF-specific region (BRSR) suppressing BRAF nuclear compartmentalisation (Fig. 6B, C) . These experiments also confirm that human GFP-DBRAF (D410) has a similar subcellular distribution to the equivalent mouse GFP-DBRAF (Fig. 1A, B, C, D) .
In summary, although hetero-dimerisation and RAS binding do not regulate nuclear compartmentalisation of the full-length BRAF protein, the BRSR and CR1 are important in its cytoplasmic retention.
Analysis of phosphorylated MEK and ERK
While the above data indicate a role for the N-terminus in preventing BRAF nuclear accumulation, this may also be attributable to the suppressive effect of this domain on BRAF kinase activity [53] and therefore we investigated the link between downstream MEK-ERK activation and GFP-BRAF compartmentalisation. Using fractionation followed by immunoprecipitation and kinase cascade assays, we found that nuclear GFP-DBRAF had similar levels of kinase activity towards MEK-ERK as cytoplasmic GFP-DBRAF (Fig. 7A ) and could bind to phosphorylated and nonphosphorylated forms of MEK and ERK (Fig. 7B) . As a control, analysis of GFP alone showed negligible kinase activity and no binding to phosphorylated or nonphosphorylated MEK/ERK (Fig. 7A, B) .
We monitored the compartmentalisation of MEK and ERK following expression of GFP, GFP-DBRAF, GFP-FL-WT BRAF and GFP-FL-VE BRAF in NIH3T3 cells using fractionation. In all cases, non-phosphorylated MEK1/2 and ERK2 were predominantly cytoplasmic and this distribution was not noticeably different between samples (Fig. 7C) . As expected from the data shown in Fig. 7B , monomeric GFP did not induce detectable MEK or ERK phosphorylation (Fig. 7C) . In contrast, all forms of GFP-BRAF induced accumulation of phosphorylated ERK (PP-ERK) in the nucleus (Fig. 7C) , although the levels of nuclear PP-ERK were significantly higher in the cells expressing the oncogenic mutants DBRAF and V600E BRAF (Fig. 7C, D) . Intriguingly, although all GFP-BRAF forms induced MEK phosphorylation (PP-MEK), its distribution was noticeably different in that it accumulated in the nucleus to a significantly greater extent in the case of GFP-DBRAF than either GFP-FL-WT BRAF or GFP-FL-VE BRAF (Fig. 7C, D) . This is a surprising result given that phosphorylated and non-phosphorylated forms of MEK are normally actively exported out of the nucleus through its NES [29] .
To further examine the link between GFP-BRAF compartmentalisation and phosphorylated MEK-ERK, high content microscopy (HCM) was utilised to allow the monitoring of thousands of cells. Initial analysis confirmed strong GFP-DBRAF nuclear compartmentalisation and lower levels of GFP-FL-WT BRAF in the nucleus following LMB treatment of the cells (Fig. 8A) . By utilising the same method as that described above for determining the proportion of GFP-BRAF in the nucleus We then undertook simultaneous PP-ERK or PP-MEK immunofluorescence (Fig. 8B, C ). This revealed that nuclear PP-ERK and PP-MEK levels were typically higher for GFP-DBRAF than GFP-FL-WT BRAF and this distinction was more pronounced for PP-MEK, consistent with the fractionation data (Fig. 7C, D) . Both nuclear GFP-DBRAF and nuclear GFP-FL-BRAF showed positive correlations with nuclear PP-ERK ( Fig. 8B ; correlation coefficients of 0.66 and 0.51 respectively) and with nuclear PP-MEK ( Fig. 8C ; correlation coefficients of 0.79 and 0.37 respectively). There were statistically significant differences between the correlation coefficients of GFP-DBRAF and GFP-FL-BRAF for both PP-ERK and PP-MEK, but this was particularly marked for PP-MEK (Z score of 45.64 compared to 14.67
for PP-ERK). In contrast, mock and GFP-transfected cells showed negligible PP-MEK or PP-ERK staining by immunofluorescence analysis (Fig. S5) . Thus, over a broad range of expression levels, truncation of BRAF caused a marked increase in nuclear PP-MEK and a more modest increase in nuclear PP-ERK, consistent with the fractionation data (Fig. 7C, D) . Similar relationships were seen in control cells and in cells stimulated for 15 or 120 min with PDGF (Fig. S6) .
We attempted to use other methods to manipulate MEK-ERK activity, particularly BRAF and MEK inhibitors. However, interpretation of these experiments was complicated by the fact that we observed altered BRAF expression levels in all compartments (unpublished observations), presumably due to feedback regulation of BRAF protein stability by the ERK pathway as previously reported [54, 55] .
Discussion
An overwhelming body of evidence has shown that the BRAF protein kinase, in its inactive conformation, is located in the cytoplasm as part of a multiprotein complex Representative digital images are shown. Cells were sorted into bins as described in Materials andMethods. The data in the graph are population averages (in AFU) from 3 repeat experiments, each with duplicate adenovirus infections and 500e600 cells per infection. Correlation coefficients (r) were determined for each dataset, converted to Z scores and compared to generate the p value indicated. containing 14-3-3 adaptor/scaffold proteins and heat-shock protein chaperones [12] .
Following upstream stimulation by ligand-activated receptor tyrosine kinases, BRAF forms a network of interacting kinases including ARAF, CRAF and KSR1/2 that bind to RAS.GTP at the plasma membrane, leading to RAF phosphorylation of MEK1/2, which in turn activates ERK1/2 [52] . Despite this widelyaccepted model of BRAF regulation, a number of other subcellular locations have been reported for BRAF [27, 28, 29, 30, 31, 32, 56] . Here, using fluorescence imaging and fractionation of tagged, exogenous proteins expressed in NIH3T3 cells, we provide evidence in support of the location of wild-type and oncogenic forms of full length BRAF in the cytoplasm of the cell. However, we also show that Nterminally deleted forms of tagged BRAF can accumulate in the nucleus when over-expressed in NIH3T3 cells, in contrast to N-terminally deleted CRAF. This difference is observed regardless of the type of tag used to monitor the truncated proteins.
N-terminally truncated forms of BRAF and CRAF were originally identified as the transforming proteins expressed within mouse and avian oncogenic retroviruses [1] .
Extensive biochemical studies on these truncated proteins showed they carry constitutive serine/threonine protein kinase activity with the ability to activate the downstream MEK/ERK pathway [1] . In particular, RAF-hbER fusion proteins expressed in NIH3T3 have been widely used as tools to unravel downstream RAF effects [38, 48, 49] . Our finding that DBRAF and DCRAF have different distributions between the nuclear and cytoplasmic compartments (Figs. 1 and 2) should be taken into consideration alongside these data as, clearly, this could impact on underpinning mechanisms. Indeed, the observation that DBRAF:ER has stronger activity towards the MEK/ERK pathway than DCRAF:ER [38] may be related to their different distributions within the cell.
The differences in the compartmentalisation of GFP-tagged, N-terminally truncated as opposed to full-length BRAF is also interesting and potentially has implications for cancers bearing single nucleotide variants as opposed to structural variants of BRAF. However, as a next step, it will be important to track the expression of endogenous RAF proteins in normal and cancer cells, and under different conditions, in order to confirm the findings from the over-expression studies. Development of a specific BRAF antibody for immunofluorescence will be important for this and/or the introduction of a protein tag into the endogenous RAF genes using genetic modification.
A widely accepted paradigm for nuclear import is that small proteins of <40KDa can freely translocate through the Nuclear Pore Complex (NPC) while proteins of a larger mass use an energy-dependent mechanism involving selective transport machinery. The DBRAF-GFP and DBRAF:ER fusion proteins used in this study have molecular masses of w65KDa and w68KDa respectively, suggesting they are too large to transit to the nucleus by diffusion, while monomeric GFP at w27KDa is able to transit by diffusion. Consistently, the accumulation of the larger KIAA1549-BRAF fusion protein (w102KDa) in the nucleus argues against a diffusion mechanism (Fig. 3C) . However, our data also exclude a role of energydependent selective transport that relies on the classical NLS-dependent import mechanism in the nuclear import of DBRAF (Fig. 4) . Therefore, the mode of nuclear import of DBRAF is currently not clear. The fact that DBRAF accumulates in the nucleus in the same cells that have also accumulated PP-MEK and PP-ERK in the nucleus (Figs. 7 and 8 ) and that nuclear DBRAF can bind to PP-MEK/PP-ERK in co-immunoprecipitation studies (Fig. 7B) raises the possibility that they are imported as a complex.
ERK translocation occurs through both passive and facilitated processes, with some evidence showing that non-phosphorylated monomeric ERK is translocated by diffusion while phosphorylated dimeric ERK requires energy for nuclear import [17, 57] . The lack of a conventional NLS sequence in ERK and importinab binding has questioned the mechanisms associated with its active nuclear import, although there is some evidence to show that phosphorylation of an SPS motif in the ERK kinase insertion domain, allows for interaction with importin7 and nuclear import [24, 58] . Critical to passive and facilitated nuclear import of ERK is its interaction with NPC proteins, the nucleoporins [59] . Not only is this important for ERK nuclear entry, but ERK phosphorylation of FG-contain nucleoporins NUP50, NUP153 and NUP214 has been shown to regulate their affinity for importinb, thus inhibiting nuclear protein import [59] . It will be interesting to further examine the involvement of ERK in DBRAF nuclear import and whether DBRAF is also involved in the regulation of generalised nuclear protein import by ERK.
Although MEK is also translocated to the nucleus through passive and facilitated mechanisms, it is rarely detected in the nucleus due to its possession of a NES, which allows for its rapid nuclear export. The fact that PP-MEK accumulates in the nucleus in the presence of DBRAF suggests interference with the nuclear export of PP-MEK, possibly by DBRAF acting as an anchor for MEK in the nucleus or by interfering with its NES. The localisation of PP-MEK in the nucleus is unusual and may have physiological significance. Nuclear accumulation of phosphorylated MEK has been previously linked with MEK acetylation [60] , prolongation of MEK-ERK activation [61] , enhancement of colon carcinogenesis [61] and the generation of polyploidy [62] . It will be important to examine if N-terminally truncated BRAF, as detected in several human cancers, is linked with phosphorylated MEK nuclear accumulation and whether this is associated with any of the key biochemical and cellular characteristics previously linked with aberrant MEK localisation.
Our data also exclude the involvement of RAF heterodimerisation and RAS interaction (Fig. 5A , B, C) in tethering full length BRAF in the cytoplasm but we show the importance of the BRSR and CR1 domain (Fig. 6) . Although we did not detect a canonical NES in the BRAF protein sequence, we cannot as yet rule out a role of a noncanonical NES in the location of full-length BRAF. The RAF N-terminal domain auto-inhibits RAF activity through intramolecular interaction with the kinase domain [53] , suggesting a possible role of deregulated BRAF catalytic activity in BRAF distribution within the cell. However, this cannot be the only contributing factor as the constitutively active DBRAF and V600E BRAF mutants have different locations. Clearly, further studies are required to unravel the mechanisms by which DBRAF translocation to the nucleus becomes possible and the role of BRAF kinase activity in this. So far, it has not been possible to use BRAF or MEK inhibitors since these are known to influence BRAF protein stability [55, 63] .
In summary, our data provide evidence for the accumulation of over-expressed, exogenous, N-terminally truncated forms of BRAF in the nucleus of the cell and that this is accompanied by the accumulation of phosphorylated MEK and ERK in the nucleus. Clearly, further studies will be needed to validate these data by tracking the intracellular distribution of endogenous proteins in normal and cancer cells. Nevertheless, our data is important to consider in the aetiology of cancers expressing N-terminally deleted forms of BRAF including splice variants that arise in tumours with acquired resistance to the BRAF inhibitor vemurafenib [9] .
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